Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - An Indian generic drug maker cannot be halted from manufacturing and selling a generic version of Roche's locally patented lung cancer drug Tarceva (erlotinib) in what a spokesman for the Mumbai-based company said was a "landmark" ruling under the country's three-year-old patent regime
You may also be interested in...
Glivec and Tarceva Patent Cases Failed Because Evidence Of Efficacy Overlooked – IP Attorney
Despite industry criticism of India's patent enforcement system, recent IP cases, such as the Tarceva and Glivec cases, have demonstrated India's High Courts' ability to enforce judgments and reach well-reasoned conclusions with relative speed, according to Schiff Hardin attorney Christopher Ohly
Glivec and Tarceva Patent Cases Failed Because Evidence Of Efficacy Overlooked – IP Attorney
Despite industry criticism of India's patent enforcement system, recent IP cases, such as the Tarceva and Glivec cases, have demonstrated India's High Courts' ability to enforce judgments and reach well-reasoned conclusions with relative speed, according to Schiff Hardin attorney Christopher Ohly
Indian Court Restrains Cipla From Exporting Generic Tarceva
NEW DELHI - The Delhi High Court ordered Indian drugmaker Cipla to refrain from exporting a generic version of Roche's locally patented lung cancer drug Tarceva (erlontinib) to nations where the Swiss company has patent registration for the product, a court official said